PAG
TBIO

Private Advisor Group’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Private Advisor Group’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-175
Closed -$3K – 3815
2020
Q2 		$3K Buy
+175
New +$2.64K ﹤0.01% 3511

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Private Advisor Group's TBIO Position: Q3 2020 in Review

Private Advisor Group sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2020, closing a stake of 175 shares — an estimated $3K sold.

Private Advisor Group first reported a position in TBIO in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 132 funds tracked by Wall St. Rank hold TBIO as of Q3 2020.

  • Private Advisor Group reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 175 Translate Bio, Inc. Common Stock shares in Q3 2020, an estimated $3K.
  • Private Advisor Group first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Translate Bio, Inc. Common Stock position peaked at $3K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.